Skip To Main Content
Levim Biotech on Muck Rack

Levim Biotech

As seen in: Diabetes Research and Clinical Practice
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Levim

Contact Levim, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 Diabetes Mellitus

|
By Kadalmani Krishnan, Levim Biotech, Srikar Raman, C.R. Anand Moses
| Diabetes Research and Clinical Practice Verified
Highlights: • This study was undertaken to compare the efficacy and safety of ‘Levim liraglutide’ biosimilar to the original reference drug. The primary efficacy endpoint was mean change in reduction in HbA1c% from baseline at week 24 compared with reference liraglutide. Analysis for treatment difference showed non-inferiority for Levim liraglutide at margin of 0.4% and one-sided alpha of 0.025.
Open in Who Shared Issue with article?
See all 1 articles